Synthetic DNA company announces conversion of series A preferred stock.

2004 MAR 1 - (NewsRx.com & NewsRx.net) -- Hybridon, Inc., (HBY) announced that essentially all its shares of outstanding series A preferred stock has been converted into 21.2 million shares of common stock.

These conversions raise the total number of shares of common stock outstanding to approximately 84.9 million.

At a special meeting of stockholders, held on December 4, 2003, the company's stockholders approved amendments to Hybridon's Restated Certificate of Incorporation that reduced the liquidation preference and annual dividend rate on the company's series A preferred stock. Prior to this agreement, the series A preferred stock, as a class, held a …